Cost-effectiveness of adding oseltamivir to primary care for influenza-like-illness: economic evaluation alongside the randomised controlled ALIC4E trial in 15 European countries
-
Published:2022-09-22
Issue:
Volume:
Page:
-
ISSN:1618-7598
-
Container-title:The European Journal of Health Economics
-
language:en
-
Short-container-title:Eur J Health Econ
Author:
Li XiaoORCID, Bilcke JokeORCID, van der Velden Alike W.ORCID, Bruyndonckx RobinORCID, Coenen SamuelORCID, Bongard EmilyORCID, de Paor Muirrean, Chlabicz SlawomirORCID, Godycki-Cwirko Maciek, Francis NickORCID, Aabenhus RuneORCID, Bucher Heiner C., Colliers Annelies, De Sutter AnORCID, Garcia-Sangenis AnaORCID, Glinz DominikORCID, Harbin Nicolay J.ORCID, Kosiek Katarzyna, Lindbæk Morten, Lionis ChristosORCID, Llor CarlORCID, Mikó-Pauer Réka, Radzeviciene Jurgute Ruta, Seifert BohumilORCID, Sundvall Pär-DanielORCID, Touboul Lundgren Pia, Tsakountakis Nikolaos, Verheij Theo J., Goossens Herman, Butler Christopher C., Beutels PhilippeORCID, Bongard EmilyORCID, de Paor Muirrean, Chlabicz SlawomirORCID, Godycki-Cwirko Maciek, Francis NickORCID, Aabenhus RuneORCID, Bucher Heiner C., Colliers Annelies, De Sutter AnORCID, Garcia-Sangenis AnaORCID, Glinz DominikORCID, Harbin Nicolay J.ORCID, Kosiek Katarzyna, Lindbæk Morten, Lionis ChristosORCID, Llor CarlORCID, Mikó-Pauer Réka, Radzeviciene Jurgute Ruta, Seifert BohumilORCID, Sundvall Pär-DanielORCID, Touboul Lundgren Pia, Tsakountakis Nikolaos,
Abstract
Abstract
Background
Oseltamivir is usually not often prescribed (or reimbursed) for non-high-risk patients consulting for influenza-like-illness (ILI) in primary care in Europe. We aimed to evaluate the cost-effectiveness of adding oseltamivir to usual primary care in adults/adolescents (13 years +) and children with ILI during seasonal influenza epidemics, using data collected in an open-label, multi-season, randomised controlled trial of oseltamivir in 15 European countries.
Methods
Direct and indirect cost estimates were based on patient reported resource use and official country-specific unit costs. Health-Related Quality of Life was assessed by EQ-5D questionnaires. Costs and quality adjusted life-years (QALY) were bootstrapped (N = 10,000) to estimate incremental cost-effectiveness ratios (ICER), from both the healthcare payers’ and the societal perspectives, with uncertainty expressed through probabilistic sensitivity analysis and expected value for perfect information (EVPI) analysis. Additionally, scenario (self-reported spending), comorbidities subgroup and country-specific analyses were performed.
Results
The healthcare payers’ expected ICERs of oseltamivir were €22,459 per QALY gained in adults/adolescents and €13,001 in children. From the societal perspective, oseltamivir was cost-saving in adults/adolescents, but the ICER is €8,344 in children. Large uncertainties were observed in subgroups with comorbidities, especially for children. The expected ICERs and extent of decision uncertainty varied between countries (EVPI ranged €1–€35 per patient).
Conclusion
Adding oseltamivir to primary usual care in Europe is likely to be cost-effective for treating adults/adolescents and children with ILI from the healthcare payers’ perspective (if willingness-to-pay per QALY gained > €22,459) and cost-saving in adults/adolescents from a societal perspective.
Funder
European Commission
Publisher
Springer Science and Business Media LLC
Subject
Health Policy,Economics, Econometrics and Finance (miscellaneous)
Reference38 articles.
1. WHO surveillance case definitions for ILI and SARI. https://www.who.int/influenza/surveillance_monitoring/ili_sari_surveillance_case_definition/en/ 2. Bilcke, J., Coenen, S., Beutels, P.: Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. PLoS ONE 9(7), e102634 (2014) 3. Influenza – estimating burden of disease. https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza 4. Uyeki, T.M., Bernstein, H.H., Bradley, J.S., Englund, J.A., File, T.M., Fry, A.M., Gravenstein, S., Hayden, F.G., Harper, S.A., Hirshon, J.M., et al.: Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clin. Infect. Dis. 68(6), 895–902 (2019) 5. Public Health England: PHE guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. In: Public Health England (2019)
|
|